Live
BioPharma DiveWhat is your AI drug repurposing strategy missing?FierceBiotech‘Real momentum’ or ‘completely absurd’? How Trump’s support has shaken up psychedelicsCytiva (Google News)Rockwell Automation and Cytiva join hands to accelerate digital transformation for biopharma companies - BioSpectrum AsiaCytiva (Google News)Rockwell Automation and Cytiva Introduce Figurate SCADA: Addressing Digital Fragmentation in Biopharma Manufacturing - ARCweb.comLonza NewsAntibody Drug Conjugates Contract Market: North America Leads; - openPR.comFierceBiotechScaling theranostics through access, safety and trustEndpoints NewsUCB bets $2 billion on Candid's T cell engager ambitionsIlluminaWilkins Investment Counsel Inc. Trims Stake in Illumina, Inc. $ILMN - MarketBeatSamsung Biologics(LEAD) Samsung Biologics labor union set to resume talks with management on Monday - Yonhap News Agency10x Genomics News10x Genomics stock up on Atera launch, spatial biology scale enhanced - MSNBio-RadBio-Rad expands antibody portfolio for biologics bioanalysis and drug monitoring - Laboratory TalkSamsung BiologicsFirst strikes in Samsung Biologics' 15-year history put labor relations to test - The Korea Herald
Agilent Jan 24, 2026

Is It Time To Reconsider Agilent Technologies (A) After Recent Share Price Weakness - Yahoo Finance

Is It Time To Reconsider Agilent Technologies (A) After Recent Share Price Weakness - Yahoo Finance

Original
Body unavailable. Use the original source.